France, January 8, 2018, 5.45pm CET – TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces its financial calendar for 2018.
Wednesday, January 24, 2018 Q4 2017 financial information (post-market)
Wednesday, March 14, 2018 Full-year 2017 financial results (post-market)
Wednesday, April 25, 2018 Q1 2018 financial information (post-market)
Thursday, April 26, 2018 Annual Shareholders’ Meeting
Thursday, July 19, 2018 Q2 2018 financial information (post-market)
Wednesday, September 19, 2018 Half-year 2018 financial results (post-market)
Wednesday, November 7, 2018 Q3 2018 financial information (post-market)
This schedule is indicative and subject to change.
Shareholders are invited to consult the Investor section of TxCell’s website www.txcell.com, which includes all financial information on the Company.
TxCell’s shares are eligible to the Euronext Paris Deferred Settlement Service (SRD), on the “Long-only” segment, and to the PEA-PME plan. TxCell is notably included in the following stock indices: CAC All Shares, CAC Mid & Small, CAC Healthcare and Next Biotech.